D&O | Jotup

Arbe Announces Q4 and Full Year 2023 Financial Results

Retrieved on:

Jeudi, mars 7, 2024

Total, OEM, Radar, TEL, Original equipment manufacturer, ADAS, Tier 1, TAM, Entrepreneurship, Perception, Safety, RFQ, D&O, Insurance, Tel Aviv Stock Exchange

TEL AVIV, Israel, March 7, 2024 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ: ARBE) ("Arbe"), a global leader in Perception Radar Solutions, today announced financial results for its fourth quarter and full year ended on December 31, 2023.

Key Points:

TEL AVIV, Israel, March 7, 2024 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ: ARBE) ("Arbe"), a global leader in Perception Radar Solutions, today announced financial results for its fourth quarter and full year ended on December 31, 2023.
Gross margin in Q4 2023 was a negative 54.5%, compared to a negative gross margin of 45.6% in Q4 2022.
Operating expenses in Q4 2023 were $11.9 million, compared to $14.0 million in Q4 2022.
2023 Net loss included financial income of $3.4 million compared to $7.2 million of financial income in 2022.

Best’s Commentary: Despite Heightened Risks, Casualty Reinsurance Renewals See Modest Price Changes

Retrieved on:

Jeudi, février 15, 2024

Banking, Professional Services, Insurance, Finance, D&O, News, AM Best, Data, Weather, ALL, Investment

The Best’s Commentary, “Despite Heightened Risks, Casualty Reinsurance Renewals See Modest Price Changes,” states that reinsurers also maintained underwriting discipline relative to volatile property covers, with attachment points, and terms and conditions unlikely to be relaxed any time soon.

Key Points:

The Best’s Commentary, “Despite Heightened Risks, Casualty Reinsurance Renewals See Modest Price Changes,” states that reinsurers also maintained underwriting discipline relative to volatile property covers, with attachment points, and terms and conditions unlikely to be relaxed any time soon.
More frequent and severe weather events have resulted in multiple price increases for property catastrophe reinsurance over the past few years.
However, reinsurers remain hesitant to allocate more capital to these exposures until there are clearer indications that technical rate adequacy has been achieved.
The trade-off between property catastrophe reinsurance and casualty reinsurance was very much a factor during the latest renewal season, according to the report.

Diligent Launches Director & Officer Questionnaire Time-Saving Templates, Reducing Regulatory Risk and Ensuring Data Security

Retrieved on:

Vendredi, février 2, 2024

Partnership, GRC, Diligence, Disclosure, Civil Service (United Kingdom), Annual report, Latham & Watkins, Risk, Public company, D&O, Organization, Risk management

NEW YORK, Feb. 2, 2024 /PRNewswire/ -- Diligent, a leading GRC SaaS company, today announced the launch of Director & Officer (D&O) questionnaire templates within the Diligent One Platform. Launched in partnership with Latham & Watkins, a leading global law firm with one of the largest public company representation practices in the world, the questionnaire templates will enable organizations to seamlessly collect information required for disclosure in the Annual Report on Form 10-K and Proxy Statement that is filed with the US Securities and Exchange Commission (SEC).

Key Points:

"Building questionnaires from scratch to collect the right information from board members and executives to meet regulatory requirements takes more time than it should," said Nithya B. Das, Chief Legal & Administrative Officer at Diligent.
"Through partnerships with leading law firms like Latham & Watkins, we're thrilled to help governance teams reduce regulatory risk, develop questionnaires faster and ensure a secure experience every step of the way."
A completely customizable format with questions covering a director or officer's background, compensation, skills, qualifications, and diversity, among other areas.
Latham's focus on innovation is a hallmark of our firm, and the collaboration with Diligent exemplifies our innovative, market-leading practice."

International Towers by Zurich adds Side A-only D&O insurance policy

Retrieved on:

Jeudi, février 1, 2024

Policy, Security (finance), Securities Class Action, SCA, Strategy, Zurich Insurance Group, Side, Insurance, Communication, Risk, Lead, D&O

SCHAUMBURG, Ill., Feb. 1, 2024 /PRNewswire/ -- Zurich American Insurance Company, a member company of Zurich North America, has added a standalone Side A Directors & Officers insurance coverage option for U.S.-based multinational companies with non-U.S. board members and officers. The new Side A-only D&O policy, called International Towers by Zurich Executive Universal Select, addresses a critical need for non-U.S. directors and officers: It helps protect their personal financial assets if they are faced with a management liability lawsuit and their company cannot cover their legal costs due to local laws, court orders or other reasons. These are known as non-indemnifiable losses.

Key Points:

The new policy, the latest addition to the award-winning International Towers by Zurich suite of D&O solutions, goes beyond fulfilling this essential need.
The International Towers by Zurich Executive Universal Select policy includes the following:
A Master Policy issued to the U.S. parent that covers Side A D&O risk for non-U.S. directors and officers only.
The International Towers by Zurich Executive Universal Select policy provides a separate limit for losses outside the U.S.
Another differentiator is that International Towers by Zurich policies can be purchased from Zurich without Zurich being the Primary or Lead Side A carrier on the customer's U.S. D&O tower.
International Programs by Zurich (IPZ) has earned a reputation for innovative solutions, winning three awards from Business Insurance in the past two years, including one in 2022 for the original International Towers by Zurich .

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on:

Jeudi, janvier 25, 2024

HF, Patient, Total, Employment, Advertising, Medicare, Insurance, Food, Safety, CMS, FDA, D&O, Marketing, Telephone, OPPS, Use, Trial of the century, Physician, Growth, Cryptocurrency

Revenue was $11.3 million for the three months ended December 31, 2023, an increase of $4.1 million, or 58%, over the three months ended December 31, 2022.

Key Points:

Revenue was $11.3 million for the three months ended December 31, 2023, an increase of $4.1 million, or 58%, over the three months ended December 31, 2022.
HF revenue units in the U.S. totaled 330 and 193 for the three months ended December 31, 2023 and 2022, respectively.
HF revenue in the U.S. totaled $10.2 million and $6.0 million for the three months ended December 31, 2023 and 2022, respectively.
As of December 31, 2023, the Company had a total of 178 active implanting centers, as compared to 159 as of September 30, 2023.

Cohen Ziffer Frenchman & McKenna Promotes Nicholas Maxwell to Partner

Retrieved on:

Mardi, janvier 9, 2024

Professional Services, Legal, Insurance, Viacom, Conduent, Medicaid, Policy, Multimedia, Thomson Reuters, Law, University, Haverford College, Acquisition, D&O, Paramount Global

Cohen Ziffer Frenchman & McKenna LLP announced today that it has promoted Nicholas R. Maxwell to partner, effective January 1, 2024.

Key Points:

Cohen Ziffer Frenchman & McKenna LLP announced today that it has promoted Nicholas R. Maxwell to partner, effective January 1, 2024.
Nick becomes the second attorney Cohen Ziffer has elevated to partner since the firm launched in early 2021, a period in which Cohen Ziffer has expanded both in size and in the number of cutting-edge issues in which it is advocating for policyholders against insurance companies.
View the full release here: https://www.businesswire.com/news/home/20240109193861/en/
“Nick has a passion for insurance litigation and a talent for navigating it that applies across the full spectrum of coverage disputes,” said Robin Cohen , chair of Cohen Ziffer.
Nick joined Cohen Ziffer shortly after its founding at the start of 2021.

Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions

Retrieved on:

Jeudi, janvier 11, 2024

Osteoarthritis, Policy, Securities Class Action, Prejudice, Fault, District court, Disclosure, D&O, Security (finance)

The settlements are subject to various conditions, including confirmatory discovery in the Securities Class Action, negotiation and execution of the full settlement agreements and obtaining court approval in each action.

Key Points:

The settlements are subject to various conditions, including confirmatory discovery in the Securities Class Action, negotiation and execution of the full settlement agreements and obtaining court approval in each action.
On January 9, 2024, the Company along with the other parties to each case filed status reports in both the Securities Class Action and the Consolidated Derivative Actions, advising the respective courts of the status of the settlements in principle.
The settlements in principle do not constitute any admission of fault, wrongdoing or liability as to the Company or any other defendant.
The Company has provided disclosure relating to these legal matters in its periodic reports on Forms 10-K and 10-Q throughout the pendency of these actions.

Rule 10b-5 Securities-Fraud Litigation Exposure Stabilized in 2023

Retrieved on:

Mercredi, janvier 10, 2024

Multimedia, D&O, FY, ADR

According to the report, exposure of U.S. and non-U.S. issuers to Rule 10b-5 private securities-fraud litigation exhibited notably lower volatility throughout 2023 relative to the preceding three years.

Key Points:

According to the report, exposure of U.S. and non-U.S. issuers to Rule 10b-5 private securities-fraud litigation exhibited notably lower volatility throughout 2023 relative to the preceding three years.
The U.S. Large Cap SCA Rule 10b-5 Exposure amounts to $220.3 billion, a decrease of 24% relative to 1H 2023.
The U.S. Small Cap SCA Rule 10b-5 Exposure amounts to $7.3 billion, a modest increase of 2% relative to 1H 2023.
The ADR SCA Rule 10b-5 Exposure decreased from $16 billion to $10.8 billion, or -32% relative to 1H 2023.

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

Retrieved on:

Mercredi, novembre 29, 2023

Research, CHF, Q&A, Participation, Insurance, G&A, D&O, Biology, Research fellow, Cryptocurrency

During the nine-months ended September 30, 2023, income increased by CHF 0.6 million to CHF 1.4 million compared to CHF 0.8 million in the nine-months ended September 30, 2022.

Key Points:

During the nine-months ended September 30, 2023, income increased by CHF 0.6 million to CHF 1.4 million compared to CHF 0.8 million in the nine-months ended September 30, 2022.
During the third quarter of 2023, income decreased by CHF 0.1 million to CHF 0.3 million compared to CHF 0.4 million in the third quarter of 2022.
Cash and cash equivalents decreased to CHF 4.8 million at September 30, 2023, compared to CHF 10.4 million at September 30, 2022.
Q3 2023 Consolidated Financial Statements:
A conference call will be held today, November 29, 2023, at 16:00 CET (15:00 GMT / 10:00 ET / 07:00 PT) to review the third quarter financial results.

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Retrieved on:

Mardi, novembre 28, 2023

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.

Key Points:

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.
“The Company is focused on developing its two lead clinical programs and maximizing its resources given market conditions.
Portage completed a $6 million financing in October 2023 for continued clinical development, general corporate and working capital purposes.
R&D costs increased by approximately $2.7 million to approximately $4.2 million, or approximately 180%, for the Fiscal 2024 Quarter from approximately $1.5 million in the Fiscal 2023 Quarter.